Previous retrospective analyses indicated that CRC patients with the KRASG13D mutation benefited from first-line chemotherapy plus cetuximab, although the absolute values of response rate, progression-free survival (PFS) and OS were still below those of patients with KRAS wild-type tumors [36, 37]. The gene discussed is KRAS; the disease is colorectal carcinoma.